Zobrazeno 1 - 10
of 446
pro vyhledávání: '"dipeptidyl-peptidase 4 inhibitors"'
Publikováno v:
Endocrine Journal, Vol 71, Iss 12, Pp 1175-1181 (2024)
Dipeptidyl peptidase 4 (DPP-4) inhibitors are new antidiabetic drugs. Their effects on the respiratory system remain unclear. This study aimed to determine the association between DDP-4 inhibitors and acute respiratory failure (ARF) among patients wi
Externí odkaz:
https://doaj.org/article/7eb260d4ef50435397d24c5230182a7a
Autor:
Arunkumar Krishnan, Carolin V. Schneider, Hendrik-Tobias Arkenau, Ezequiel Matias Mauro, Alejandro Forner, W. Scott Butsch, Declan Walsh, Saleh A. Alqahtani
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 38, Iss , Pp 100370- (2024)
Aim: To examine the association between the use of incretin-based drugs [glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4Is)] and the risk of cholangiocarcinoma (CCA) in the United States. Methods: This l
Externí odkaz:
https://doaj.org/article/7692fc64b12440d7bb080c8ee4890983
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 2471-2493 (2024)
Rongping Chen,1,* Jing Li,2,* Danqi Chen,3,* Weiheng Wen,1 Susu Zhang,1 Jitong Li,1 Yuting Ruan,1 Zhen Zhang,1 Jia Sun,1 Hong Chen1 1Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republ
Externí odkaz:
https://doaj.org/article/df38dcf4a82f4cf791aed65429204bec
Autor:
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, Ivan Pristaš, Ognjen Brborović, Hana Brborović
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract There is a scarcity of information on the population with diabetes mellitus type 2 and cardiomyopathy (PDMC) in COVID-19, especially on the association between anti-diabetic medications and COVID-19 outcomes. Study is designed as a retrospec
Externí odkaz:
https://doaj.org/article/ccd5faca0b2744be8ccf749fe414a26a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vanessa C. Brunetti, Audray St-Jean, Sophie Dell’Aniello, Anat Fisher, Oriana H. Y. Yu, Shawn C. Bugden, Jean-Marc Daigle, Nianping Hu, Silvia Alessi-Severini, Baiju R. Shah, Paul E. Ronksley, Lisa M. Lix, Pierre Ernst, Kristian B. Filion, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Publikováno v:
BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Characteristics of patients using newer 2nd and 3rd line antidiabetic drugs in a real-world setting are poorly understood. We described the characteristics of new users of sodium-glucose co-transporter-2 inhibitors (SGLT-2i), dipe
Externí odkaz:
https://doaj.org/article/4dd7ea64c43847aeb774db5960cf2f58
Autor:
Florence Hui Sieng Tan, Chin Voon Tong, Xun Ting Tiong, Bik Kui Lau, Yueh Chien Kuan, Huai Heng Loh, Saravanan Vengadesa Pillai
Publikováno v:
Journal of the ASEAN Federation of Endocrine Societies, Vol 36, Iss 2 (2022)
Objective. To evaluate the effect of adding DPP4 inhibitor (DPP4-I) on glycemic variability (GV) in patients with type 2 diabetes mellitus (T2DM) treated with premixed human insulin (MHI). Methodology. We conducted a prospective study in patients w
Externí odkaz:
https://doaj.org/article/2f0222bd7b0c457e900a2d6ef08295d9
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Several new antidiabetic medicines (GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors) have been approved by the European Medicines Agency since 2006. The aim of this study was to evaluate the uptake of new antidiab
Externí odkaz:
https://doaj.org/article/fbb2002b5a764158b5e4b61dc9c732a4
Autor:
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid
Publikováno v:
BMC Endocrine Disorders, Vol 21, Iss 1, Pp 1-5 (2021)
Abstract Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid. The objective of our study was t
Externí odkaz:
https://doaj.org/article/51472d51ecc54800893418b0912badfc